Your browser doesn't support javascript.
loading
Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.
Hagedorn, Peter H; Pontoppidan, Malene; Bisgaard, Tina S; Berrera, Marco; Dieckmann, Andreas; Ebeling, Martin; Møller, Marianne R; Hudlebusch, Heidi; Jensen, Marianne L; Hansen, Henrik F; Koch, Troels; Lindow, Morten.
Afiliação
  • Hagedorn PH; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
  • Pontoppidan M; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
  • Bisgaard TS; Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kgs. Lyngby, Denmark.
  • Berrera M; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
  • Dieckmann A; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Ebeling M; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Møller MR; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • Hudlebusch H; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
  • Jensen ML; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
  • Hansen HF; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
  • Koch T; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
  • Lindow M; Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Copenhagen, DK-2970 Hørsholm, Denmark.
Nucleic Acids Res ; 46(11): 5366-5380, 2018 06 20.
Article em En | MEDLINE | ID: mdl-29790953
ABSTRACT
Antisense oligonucleotides that are dependent on RNase H for cleavage and subsequent degradation of complementary RNA are being developed as therapeutics. Besides the intended RNA target, such oligonucleotides may also cause degradation of unintended RNA off-targets by binding to partially complementary target sites. Here, we characterized the global effects on the mouse liver transcriptome of four oligonucleotides designed as gapmers, two targeting Apob and two targeting Pcsk9, all in different regions on their respective intended targets. This study design allowed separation of intended- and off-target effects on the transcriptome for each gapmer. Next, we used sequence analysis to identify possible partially complementary binding sites among the potential off-targets, and validated these by measurements of melting temperature and RNase H-cleavage rates. Generally, our observations were as expected in that fewer mismatches or bulges in the gapmer/transcript duplexes resulted in a higher chance of those duplexes being effective substrates for RNase H. Follow-up experiments in mice and cells show, that off-target effects can be mitigated by ensuring that gapmers have minimal sequence complementarity to any RNA besides the intended target, and that they do not have exaggerated binding affinity to the intended target.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Mensageiro / Terapia Genética / Oligonucleotídeos Antissenso / RNA Complementar / Ribonuclease H / Ácidos Nucleicos Heteroduplexes Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Mensageiro / Terapia Genética / Oligonucleotídeos Antissenso / RNA Complementar / Ribonuclease H / Ácidos Nucleicos Heteroduplexes Idioma: En Ano de publicação: 2018 Tipo de documento: Article